ATE209507T1 - Transfer von molekülen in das zytosol von zellen durch photosensibilisierende substanzen - Google Patents

Transfer von molekülen in das zytosol von zellen durch photosensibilisierende substanzen

Info

Publication number
ATE209507T1
ATE209507T1 AT95932244T AT95932244T ATE209507T1 AT E209507 T1 ATE209507 T1 AT E209507T1 AT 95932244 T AT95932244 T AT 95932244T AT 95932244 T AT95932244 T AT 95932244T AT E209507 T1 ATE209507 T1 AT E209507T1
Authority
AT
Austria
Prior art keywords
cells
molecules
cytosol
transfer
photosensitizing substances
Prior art date
Application number
AT95932244T
Other languages
English (en)
Inventor
Kristian Berg
Kirsten Sandvik
Johan Moan
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Application granted granted Critical
Publication of ATE209507T1 publication Critical patent/ATE209507T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Catalysts (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95932244T 1994-09-08 1995-09-04 Transfer von molekülen in das zytosol von zellen durch photosensibilisierende substanzen ATE209507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO943327A NO180167C (no) 1994-09-08 1994-09-08 Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
PCT/NO1995/000149 WO1996007432A1 (en) 1994-09-08 1995-09-04 Transfer of molecules into the cytosol of cells

Publications (1)

Publication Number Publication Date
ATE209507T1 true ATE209507T1 (de) 2001-12-15

Family

ID=19897382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95932244T ATE209507T1 (de) 1994-09-08 1995-09-04 Transfer von molekülen in das zytosol von zellen durch photosensibilisierende substanzen

Country Status (19)

Country Link
US (3) US5876989A (de)
EP (1) EP0783323B1 (de)
JP (1) JP4148328B2 (de)
KR (2) KR100529967B1 (de)
CN (1) CN1222309C (de)
AT (1) ATE209507T1 (de)
AU (1) AU700797B2 (de)
BR (1) BRPI9508825B8 (de)
CA (1) CA2199290C (de)
CZ (1) CZ65897A3 (de)
DE (1) DE69524238T2 (de)
ES (1) ES2163527T3 (de)
FI (1) FI121328B (de)
HU (1) HU222984B1 (de)
MX (1) MX9701676A (de)
NO (1) NO180167C (de)
NZ (2) NZ509519A (de)
PT (1) PT783323E (de)
WO (1) WO1996007432A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6210356B1 (en) * 1998-08-05 2001-04-03 Ekos Corporation Ultrasound assembly for use with a catheter
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5995867A (en) * 1997-03-19 1999-11-30 Lucid Inc Cellular surgery utilizing confocal microscopy
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US6676626B1 (en) 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
ES2356342T3 (es) * 1998-01-05 2011-04-07 The University Of Washington Mejora de transporte utilizando agentes de alteración de membrana.
US6399769B1 (en) * 1998-01-20 2002-06-04 Kimberly-Clark Worldwide, Inc. Method of making sulfanatophenyl substituted porphines
GB9905911D0 (en) * 1999-03-15 1999-05-05 Photocure As Method
WO2001019953A1 (en) * 1999-09-09 2001-03-22 Center For Advanced Science And Technology Incubation, Ltd. Method of piercing membrane and apparatus therefor
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
DK1301213T3 (en) * 2000-07-21 2017-03-27 Revance Therapeutics Inc MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT
EP1346059B1 (de) * 2000-11-29 2012-05-23 PCI Biotech AS Photochemische internalisierung zur zuführung von molekülen in das zytosol
AU2210402A (en) 2000-11-29 2002-06-11 Norwegian Radium Hospital Res Photochemical internalization for virus-mediated molecule delivery into the cyosol
US20020098472A1 (en) * 2000-11-30 2002-07-25 Erlach Julian Van Method for inserting a microdevice or a nanodevice into a body fluid stream
US20020137901A1 (en) * 2001-01-22 2002-09-26 Cavanaugh Philip Gerard Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin
AU2002250034A1 (en) * 2001-02-08 2002-08-19 Sequitur, Inc. Methods of light activated release 0f ligands from endosomes
ATE429930T1 (de) * 2001-06-20 2009-05-15 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
GB0121023D0 (en) * 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US7220239B2 (en) 2001-12-03 2007-05-22 Ekos Corporation Catheter with multiple ultrasound radiating members
US7141044B2 (en) 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
EP1478656B1 (de) * 2002-02-01 2009-09-16 Life Technologies Corporation Oligonukleotidzusammensetzungen mit verbesserter effizienz
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
GB0215534D0 (en) * 2002-07-04 2002-08-14 Ecole Polytech Selective photochemotherapy using oligonucleotide targeting agents
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US6921371B2 (en) * 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
US7332477B2 (en) * 2003-07-10 2008-02-19 Nitto Denko Corporation Photocleavable DNA transfer agent
WO2005032597A1 (en) * 2003-09-29 2005-04-14 Nitto Denko Corporation Biodegradable polyacetals for in vivo polynucleotide delivery
US20080318319A1 (en) * 2003-12-19 2008-12-25 Yoshiko Minakuchi Novel Method of Nucleic Acid Transfer
HUE025656T2 (en) * 2004-03-03 2016-04-28 Revance Therapeutics Inc Topical application and transdermal delivery of botulinum toxins
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
US20060094781A1 (en) * 2004-11-04 2006-05-04 Syneron Medical Ltd. Method of treating extracellular matrix
FR2877943B1 (fr) * 2004-11-16 2008-09-05 Univ De Coimbra Nouveaux derives de porphyrine, notamment chlorines et/ou bacteriochlorine, et leurs applications en therapie photodynamique
ES2362301T3 (es) 2005-03-03 2011-07-01 Revance Therapeutics, Inc. Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido.
KR20070110402A (ko) 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
US7674452B2 (en) * 2005-03-16 2010-03-09 Nitto Denko Corporation Polymer coating of cells
BRPI0501037B8 (pt) 2005-03-18 2021-07-27 Fund De Amparo A Pesquisa Do Estado De Sao Paulo uso de crotamina e composição
WO2007059528A2 (en) * 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7718193B2 (en) * 2006-03-16 2010-05-18 University Of Washington Temperature- and pH-responsive polymer compositions
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
WO2008082889A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
ES2471118T3 (es) 2007-06-22 2014-06-25 Ekos Corporation Método y aparato para el tratamiento de hemorragias intracraneales
EP2231024A4 (de) * 2007-12-14 2015-03-18 Ekos Corp Ultraschallpulsformung
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
US8426214B2 (en) * 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
US20110117668A1 (en) * 2009-11-09 2011-05-19 University Of Washington Through Its Center For Commercialization Self-powered smart diagnostic devices
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
GB201208548D0 (en) 2012-05-15 2012-06-27 Pci Biotech As Compound and method
US20160040128A1 (en) 2013-03-15 2016-02-11 Pci Biotech As Method
JP6684215B2 (ja) 2013-08-28 2020-04-22 ピーシーアイ バイオテック エイエス 予防接種用化合物および免疫化用化合物、ならびに予防接種方法および免疫化方法
GB2517707B (en) * 2013-08-28 2020-09-02 Pci Biotech As A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen
AU2014390262B2 (en) 2014-04-11 2020-11-26 Pci Biotech As Method of treating melanoma
WO2016030529A1 (en) 2014-08-28 2016-03-03 Pci Biotech As Compound and method
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
CN107708581B (zh) 2015-06-10 2021-11-19 Ekos公司 超声波导管
KR20190068573A (ko) 2016-10-14 2019-06-18 피씨아이 바이오테크 에이에스 젬시타빈의 tpcs-2a 유도된 광화학 내재화로의 담관암의 치료
GB201718631D0 (en) * 2017-11-10 2017-12-27 Pci Biotech As Method
GB201801169D0 (en) * 2018-01-24 2018-03-07 Pci Biotech As Method
CA3104833A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
US11052144B2 (en) 2019-04-25 2021-07-06 Dcprime B.V. Methods of tumor vaccination
CN110711249B (zh) * 2019-09-19 2020-10-27 北京化工大学 一种溶酶体膜包覆纳米颗粒的制备方法
CA3172447A1 (en) 2020-03-27 2021-09-30 Erik Hans MANTING In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CN114163508B (zh) * 2020-09-11 2024-07-16 王月志 能破坏细胞的氨基酸序列及相关核苷酸序列和相关的应用
US20220168407A1 (en) 2020-11-05 2022-06-02 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
GB202115451D0 (en) 2021-10-27 2021-12-08 Pci Biotech As Method
IL319617A (en) 2022-09-27 2025-05-01 Pci Biotech As Method for releasing viral vectors
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product
GB202404168D0 (en) 2024-03-22 2024-05-08 Pci Biotech As Method
WO2026159592A1 (en) 2025-01-21 2026-07-30 Mendus B.V. Methods for ex vivo expansion of tumor infiltrating lymphocytes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU563827B2 (en) 1982-07-01 1987-07-23 Millipore Corp. Filtration apparatus
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4704255A (en) 1983-07-15 1987-11-03 Pandex Laboratories, Inc. Assay cartridge
US5066274A (en) * 1985-04-30 1991-11-19 Nippon Petrochemicals Company, Ltd. Tetrapyrrole therapeutic agents
US5076950A (en) 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
US4895706A (en) 1986-10-28 1990-01-23 Costar Corporation Multi-well filter strip and composite assemblies
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
NO891491D0 (no) * 1987-08-12 1989-04-11 Peter Nemeth Prosedyre for befrielse av celleblandinger og vev for uoenskede populasjoner.
HU204856B (en) 1987-08-12 1992-02-28 Orszagos Mueszaki Fejlesztesi Process for releasing cell mixtures and tissues from undesired populations and for producing monoclonal antibody - hematoporphyrin conjugates
GB8721108D0 (en) * 1987-09-08 1987-10-14 Salford University Of Liposomes
US5284647A (en) * 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5256532A (en) 1988-05-02 1993-10-26 Zynaxis Technologies, Inc. Methods, reagents and test kits for determination of subpopulations of biological entities
US4925736A (en) * 1988-07-06 1990-05-15 Long Island Jewish Medical Center Topical hematoporphyrin
GB8905001D0 (en) 1989-03-04 1989-04-19 Univ Leicester Screening for natural products of microbial metabolism
US5567687A (en) * 1989-03-06 1996-10-22 University Of Texas Texaphyrins and uses thereof
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5059619A (en) * 1989-06-14 1991-10-22 Quadra Logic Technologies, Inc. Stable freeze-dried polyhematoporphyrin ether/ester
DE3919873A1 (de) 1989-06-19 1990-12-20 Behringwerke Ag Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
GB8916859D0 (en) 1989-07-24 1989-09-06 Dynal As Hapten linking
GB8929297D0 (en) 1989-12-29 1990-02-28 Dynal As Method of separation
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5491068A (en) 1991-02-14 1996-02-13 Vicam, L.P. Assay method for detecting the presence of bacteria
US5179120A (en) * 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
PL165249B1 (pl) * 1991-10-29 1994-11-30 Wojskowa Akad Tech Sposób otrzymywania soli kompleksowych hematoporfiryny i jej pochodnych PL PL PL PL PL PL PL
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
HU217179B (hu) * 1992-03-16 1999-12-28 Isis Pharmaceuticals Inc. Oligonukleotidok, oligonukleotidtartalmú készítmények és eljárások protein kináz C expressziójának modulálására
DK0631634T3 (da) 1992-03-20 1996-06-24 Celsis Int Plc Fremgangsmåde og apparat til analyse af biologisk materiale
AU4115693A (en) * 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
WO1994007138A1 (en) 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
US5985620A (en) * 1992-11-03 1999-11-16 Gene Shears Pty. Limited TNF-α Ribozymes
FR2700010B1 (fr) 1992-12-24 1995-03-17 Rocher Yves Biolog Vegetale Méthode et dispositif pour tester la réactivité de cellules à l'égard de produits.
US5374531A (en) 1993-03-22 1994-12-20 Zynaxis, Inc. Immunoassay for determination of cells
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US5491084A (en) * 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5514340A (en) 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5872007A (en) * 1995-02-17 1999-02-16 Hybridon, Inc. CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer

Also Published As

Publication number Publication date
CN1222309C (zh) 2005-10-12
HU222984B1 (hu) 2004-01-28
AU700797B2 (en) 1999-01-14
DE69524238T2 (de) 2002-07-18
ES2163527T3 (es) 2002-02-01
NO943327D0 (no) 1994-09-08
JP4148328B2 (ja) 2008-09-10
BRPI9508825B1 (pt) 2020-12-22
AU3534795A (en) 1996-03-27
CN1164829A (zh) 1997-11-12
NO943327L (no) 1996-03-11
CZ65897A3 (en) 1997-10-15
KR20040004402A (ko) 2004-01-13
FI121328B (fi) 2010-10-15
KR100395615B1 (ko) 2003-12-31
CA2199290A1 (en) 1996-03-14
US20020155099A1 (en) 2002-10-24
NZ293008A (en) 2001-04-27
BRPI9508825B8 (pt) 2021-07-06
US5876989A (en) 1999-03-02
EP0783323B1 (de) 2001-11-28
KR100529967B1 (ko) 2005-11-22
US6680301B2 (en) 2004-01-20
EP0783323A1 (de) 1997-07-16
CA2199290C (en) 2010-10-26
WO1996007432A1 (en) 1996-03-14
BR9508825A (pt) 1998-01-06
KR970705415A (ko) 1997-10-09
US20030134813A1 (en) 2003-07-17
MX9701676A (es) 1998-04-30
FI970983L (fi) 1997-03-07
HUT77469A (hu) 1998-05-28
FI970983A0 (fi) 1997-03-07
JPH10508295A (ja) 1998-08-18
NZ509519A (en) 2004-10-29
NO180167C (no) 1997-02-26
DE69524238D1 (de) 2002-01-10
NO180167B (no) 1996-11-18
PT783323E (pt) 2002-03-28
HK1004110A1 (en) 1998-11-20

Similar Documents

Publication Publication Date Title
DE69524238D1 (de) Transfer von molekülen in das zytosol von zellen durch photosensibilisierende substanzen
ATE331802T1 (de) Sequenz-spezifische dna-rekombination in eukaryotischen zellen
DK0923592T3 (da) Fremgangsmåder til rensning af nukleinsyrer
DE69636937D1 (de) Durch trans-spaltung erhaltene therapeutische molekule
BR0012325A (pt) Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo
DE69637660D1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
AU5753598A (en) Novel genes coding for amino acid deacetylases with specificity for N-acetyl-L-phosphinothricin, their isolation and use
DK1724354T3 (da) Cirkulær DNA-molekyle med en afhængig replikationsoprindelse, fremgangsmåde til fremstilling heraf og anvendelse heraf i genterapi
ATE346156T1 (de) Umkehrtransfektionsverfahren
DE69835228D1 (de) Verfahren zur elektropermeabilisation einzelner zellulärer und organeller strukturen
ATE284898T1 (de) Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
BR9206049A (pt) Composto, processos para preparar o composto, para o reconhecimento específico por sequência de um polinucleotídio de filamento duplo, para modular a expressão de um gene em um organismo, para tratar as condições associadas com produção de proteínas indesejada em um organismo, para induzir a degradação de DNA ou RNA em células de um organismo e para exterminar células ou vírus e composição farmacêutica
ATE430558T1 (de) Herstellung von mikrokügelchen
EP1686181A3 (de) Verfahren zum verbesserten virusvermittelten DNA-Transfer unter Verwendung von Molekülen mit Virus- und Zell-bindenden Domänen
AR023482A1 (es) Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
GB2377447B (en) Isolation of dna molecules
ATE351902T1 (de) Oberflächentransfektion und expressionsverfahren
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
IL131436A0 (en) Compositions for treatment of disorders involving programmed cell death
DK1631672T3 (da) Cirkulært ekspressionskonstrukt til genterapeutiske anvendelser
BR9709700A (pt) Vetor viral célula composição farmacêtica processo de preparação in situ de moléculas de dna circulares replicativas utilização de um vetor viral processo paa a transferência de ácidos nucleícos para uma e molécula de dna circular replicativa
MX9505097A (es) 1,4-dihidropiridinas con estructura puente en la posicion 1,2, procedimiento para su obtencion y medicamentos que las contienen.
ATE295884T1 (de) Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose
ATE430806T1 (de) (-)-strang rns virusvektor für nervenzellen
WO2001011063A3 (de) Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification